Addiction one of the Largest growing Problem’s in the world today. This Press Release Service will bring you the newest services and research available.
XchangePoint is an automated solution for medication-centric targeted patient engagement that allows users to follow a patient throughout their healthcare journey. The solution’s MedSpecialty module provides users the ability to build a complete medication history profile of both specialty and traditional medications across all prescribers to offer a wholistic view of a patient’s medication and support needs. This results in the capability to then provide adherence scores for all treatments and disease states.
“XchangePoint can be customized to meet the needs of the clinical campaigns we are pursuing around our patient’s medication plan adherence,” says Sugg. “Specifically, utilizing the MedSpecialty module as a tool allows us to strategically provide proactive care and more easily navigate an often-complicated journey through the care continuum for our high-risk patient population and their loved ones.”
Physicians East’s can target high-risk patients to have their medication treatment plans reviewed and monitored. This mitigates gaps in therapy or potential drug related problems resulting in nonadherence to a prescribed treatment plan and potential adverse drug events. Timed follow-up using patient prioritized dashboards and call lists are created to consistently identify and combat any adherence barriers and help ensure compliance.
About PharmaPoint PharmaPoint is an innovative, technology-enabled pharmacy management and software company. XchangePoint, our proprietary integrated workflow management system supporting medication management across care transitions, is designed for pharmacy and care team members to drive medication optimization for at-risk patients in the acute, post-acute and ambulatory care settings. Additionally, through the management of outpatient retail pharmacies for hospitals, health systems and physician groups, our commitment to completing the care continuum results in improved patient health and satisfaction, reduced healthcare costs, and provides clients with a source of ancillary income. Headquartered in Birmingham, Ala., PharmaPoint has been recognized as one of the most innovative, inspiring and fastest growing private companies for six consecutive years by Inc. Magazine. For more information about our company, please visit http://www.pharmapoint.com.
About Physicians East Physicians East is Eastern North Carolina’s largest private, medical-surgical multispecialty health care practice with over ninety providers caring for patients in Greenville, Farmville, Winterville, Kinston, and Beulaville. Our offering includes cardiology, dermatology, diagnostics, endocrinology, endoscopy, gastroenterology, obstetrics and gynecology, hematology & oncology, integrative medicine, laboratory & pre-op, nutrition, pharmacy, primary care, pulmonary & critical care, rheumatology, sleep medicine, surgery, urgent care, urogynecology, and urology. Since 1965, Physicians East’s physicians and staff have worked together to build a reputation of excellence in individualized, comprehensive, patient-focused health care. Through its dedicated and committed staff, Physicians East sets the benchmark for providing the highest quality and most innovative medical care available. For more information about Physicians East’s services, visit http://www.physicianseast.com or call 252-752-6101.
Key benefits of the RPM Healthcare and Epic integration include:
Enhanced interoperability: Facilitating the smooth exchange of medical records and patient data, reducing duplication, and improving accuracy.
Improved patient care: Streamlined access to real-time data ensures healthcare providers can make more informed decisions and deliver higher-quality care.
Increased efficiency: Reduced administrative overhead and manual data entry, allowing healthcare providers to focus on patient outcomes.
Seamless workflows: A unified platform that empowers healthcare professionals to work more efficiently and collaborate seamlessly.
Data security: Maintaining the highest standards of data protection and patient privacy to ensure compliance with regulatory requirements.
“After close collaboration with our client’s healthcare providers, it was clear that seamless retrieval of remotely gathered patient data during office visits was crucial,” said Fabrizio Gambino, President and CCO of RPM Healthcare. “Working in tandem with our client’s IT team, we swiftly integrated real-time data into patient charts, allowing for more accurate and timely diagnoses and treatment planning.”
This announcement follows a successful integration with athenahealth’s EHR earlier this year. Both integrations are currently available to all RPM Healthcare clients through the RPM365 platform. RPM Healthcare is committed to providing exceptional customer support and training to ensure a smooth transition for its users.
For more information about the RPM Healthcare and EHR integration options, please visit rpmhealthcare.com or contact us at [email protected].
About RPM Healthcare
RPM Healthcare provides comprehensive digital health solutions that enable providers to extend patient care beyond the office, enhancing the patient experience and improving clinical outcomes. For more information, visit rpmhealthcare.com.
About Epic
Epic develops software to help people get well, help people stay well, and help future generations be healthier. Epic is a trademark of Epic Systems Corporation. Visit www.epic.com/about.
For media inquiries and interviews, please contact: Fabrizio Gambino President and CCO RPM Healthcare Phone: (888) 672-8436 Email: [email protected]
Krish Chopra, NPHub’s CEO, remarked, “Aligning with Sarah Michelle NP Reviews, a distinguished leader in NP board exam preparation, is a privilege. This collaboration is geared towards offering a holistic solution that assists students not only in securing clinical placements but also in acing their board exams. It’s a substantial stride in our mutual endeavor to foster the growth and success of nurse practitioners.”
The mission of Sarah Michelle NP Reviews dovetails with addressing the central hurdles nurse practitioner students encounter: passing their board exams and securing clinical placements. With an established legacy of assisting students in excelling in their boards, this collaboration with NPHub underscores their dedication to nurturing the educational and professional advancement of NP students.
About NPHub
Helmed by CEO Krish Chopra, Atlanta-based NPHub, founded in 2017, excels in connecting graduate nursing students with seasoned preceptors for clinical practicum placements. NPHub’s pioneering marketplace platform meticulously considers the nature of clinical rotation, students’ geographical preferences, and specific areas of interest. With a mission in sync with bolstering nursing students in their educational quests, NPHub has played a pivotal role in enabling nearly 5,000 nurse practitioner students to graduate on time.
Founded in 2020, Sarah Michelle NP Reviews is a leading provider of premier exam prep resources geared toward helping nurse practitioner students pass their board certification exam the first time. Through a combination of content expertise, anxiety management, no-fluff courses and a supportive community, SMNP Reviews has helped over 40,000 students realize their dream of becoming a “real deal NP”. SMNP Reviews offers live study groups, self-paced courses, question banks, a question bank app and 1:1 test readiness sessions. SMNP Reviews was acquired by Blueprint Test Prep in 2022.
About Blueprint Test Prep
Founded in 2005, Blueprint Prep is the leading platform for high-stakes test prep in the U.S., offering live and self-paced online courses, private tutoring, self-study materials, and application consulting services for pre-law, pre-med, and medical school students, as well as Qbanks, tutoring, and live study groups for residents, practicing physicians, PAs and NPs via its acquisitions of Rosh Review and Sarah Michelle NP Reviews. Blueprint leverages a unique approach that combines engaging video lectures, unparalleled expertise in content creation, the latest AI-powered learning technology, and personalized study planning tools. Blueprint has produced unrivaled results, including industry-leading score increases for its pre-law and pre-med students taking the LSAT and MCAT.
Blurr’d Lines Medspa, a premier destination for cutting-edge aesthetic treatments, invites the community to its Open House event on November 15th from 5:30 pm to 7:30 pm. Attendees can expect giveaways worth over $3000, expert consultations, exclusive discounts, and more. Located at 654 State Road, Dartmouth, Massachusetts 02747, Blurr’d Lines Medspa is renowned for enhancing natural beauty safely and effectively. For event details and reservations, visit https://blurrdlines.com or contact Dr. Manuel Corriea and Jonathan RN, BSN at 508-317-0551. Spots sell quickly, so don’t miss out on this transformative beauty experience.
DARTMOUTH, Mass., Nov. 13, 2023 /PRNewswire-PRWeb/ — Blurr’d Lines Medspa, a leading destination for cutting-edge aesthetic treatments and skincare solutions and leading Morpheus8 provider, is thrilled to invite the local community to its highly anticipated Open House event on Wednesday, November 15th, from 5:30 pm to 7:30 pm. This exciting occasion promises an evening filled with beauty, education, and incredible giveaways.
Located at 654 State Road, Dartmouth, Massachusetts 02747, Blurr’d Lines Medspa has earned a reputation for providing top-tier aesthetic services that enhance the natural beauty of its clients. The Open House event is the perfect opportunity for attendees to learn more about Medspa’s innovative treatments and meet the skilled professionals behind the scenes.
“We are excited to open our doors and welcome our valued community members to Blurr’d Lines Medspa. This Open House is our way of expressing gratitude for the support we’ve received and allowing our guests to experience the transformative treatments we offer,” said Dr. Manuel Correia, cofounder of Blurr’d Lines Medspa.
Highlights of the Open House event include:
Giveaways Galore:
– One Morpheus8 Treatment (Valued at $1200) – Full Underarm Laser Hair Removal Treatment (entire series of 6) (Valued at $500) – One IPL Photo Facial (Valued at $500) – Jeuveau 50 units (Valued at $600) – Free Chemical Peel (Valued at $125) – Forma, lower face (Valued at $350)
These amazing giveaways represent a combined value of over $3000, making this event a must-attend for anyone interested in revitalizing their beauty regimen.
Expert Consultations:** Attendees will have the chance to consult with Blurr’d Lines Medspa’s experienced team of professionals, who can provide personalized recommendations and answer questions about Medspa’s services.
Exclusive Discounts:** Special offers and discounts on select treatments will be available exclusively during the Open House event.
Refreshments:** Enjoy light refreshments and beverages while mingling with fellow beauty enthusiasts.
Raffle Prizes:** Additional prizes and surprises will be up for grabs in a raffle that adds even more excitement to the evening.
Blurr’d Lines Medspa prioritizes safety and client satisfaction, ensuring that every treatment is performed with the utmost care and expertise. Whether you’re interested in non-surgical facial rejuvenation, laser hair removal, or skincare treatments, Blurr’d Lines Medspa has a solution for you.
Don’t miss this unique opportunity to discover the latest in aesthetic enhancements, receive expert guidance, and win fantastic prizes. Join us on November 15th, from 5:30 pm to 7:30 pm, at Blurr’d Lines Medspa in Dartmouth, MA. RSVP today to secure your spot at this highly anticipated event.
For more information, please visit the Blurr’d Lines Medspa website at https://blurrdlines.com
or contact: Dr. Manuel Correia
Or
Jonathan RN, BSN Phone: 508-317-0551
Spots for this event are selling quickly, so don’t delay in reserving your place! Blurr’d Lines Medspa looks forward to welcoming you to this exciting event.
About Blurr’d Lines Medspa:
Blurr’d Lines Medspa is a leading Dartmouth, MA provider of state-of-the-art aesthetic treatments and skincare solutions. Committed to enhancing natural beauty and boosting self-confidence, Medspa offers a wide range of services, all performed by skilled professionals using the latest technology. With a focus on safety, effectiveness, and client satisfaction, Blurr’d Lines Medspa is the go-to destination for those seeking transformative beauty experiences.
This collaboration brings together NovaSterilis’ deep expertise of decellularization and terminal sterilization of medical devices in their final packaging, using scCO2 technologies and Dr. Spector’s extensive experience in plastic and reconstructive surgery.
“I’m pleased to collaborate with NovaSterilis on another CAT grant,” said Dr. Jason Spector. “We will be able to leverage the knowledge gained from our previous work on the decellularization and terminal sterilization of costal cartilage. This opportunity has the potential to improve patient outcomes where soft tissue regeneration is necessary.”
The project addresses the need for a permanent, regenerative treatment in the global $6.7 billion USD dermal/soft tissue filler market. Today’s solutions are temporary and require expensive regularly scheduled medical treatments. The allograft adipose matrix dermal filler developed through the Cornell University CAT holds the promise to be a tremendous improvement in the standard of care and a reduction in cost to the healthcare system.
“We are thrilled to collaborate with Dr. Spector on this exciting project,” said Tony Eisenhut, CEO of NovaSterilis. “Our combined efforts have the potential to make a significant impact in regenerative medicine, ultimately benefiting patients and reducing costs associated with multiple treatments.”
To fulfill this engagement, NovaSterilis engaged two commercial partners in the project: Alamo Biologics (San Antonio TX) and Australian Biotechnologies (Sydney Australia) will provide manufacturing, distribution, and marketing insights, as well as years of clinician feedback on the project. These partners have over 50 years of combined experience using the scCO2 technology platform across multiple markets, including healthcare, tissue engineering, regenerative medicine, and medical device sterilization. This commercial experience coupled with the clinical and translational research knowledge of Dr. Spector will be central to the development of an integrated process that creates a structurally stable, decellularized allograft adipose matrix with preserved endogenous growth factors.
“NovaSterilis has partnered with some of the best clinical and manufacturing teams in the industry to fulfill our goal of providing scCO2 technologies that meet or exceed the highest standards for product safety and performance,” Eisenhut added.
About NovaSterilis: NovaSterilis is a leading innovator in supercritical carbon dioxide technology, dedicated to advancing environmentally friendly and efficient solutions for a wide range of applications, including tissue processing, sterilization, and decellularization of regenerative medicine matrices. With a commitment to sustainability and innovation, NovaSterilis aims to transform industries and improve lives through the power of supercritical carbon dioxide. For more information visit http://www.novasterilis.com
About Dr. Jason Spector, M.D.: Jason A. Spector, M.D., F.A.C.S. is the Chief of the Division of Plastic and Reconstructive Surgery, and a Professor of Surgery and Otolaryngology at Weill Cornell Medicine, and Adjunct Professor in the Meinig School of Biomedical Engineering at Cornell University. He is a nationally recognized board-certified plastic surgeon specializing in reconstructive microsurgery of the head and neck, breast, and lower extremities, as well as aesthetic surgery. Dr. Spector is the Director and Principal Investigator of the Laboratory for Bioregenerative Medicine and Surgery at Weill Cornell Medicine. His lab focuses on novel approaches for tissue engineering, wound healing, and precision medicine, as well as the development of various translational technologies from bench to bedside.
About Alamo Biologics: Alamo Biologics is a full-service tissue bank offering the highest quality allografts and biologics for hundreds of surgical and regenerative applications. Alamo’s turn-key services include manufacturing, storage, and distribution of allograft tissue; research and development, contract manufacturing, and biologic storage facilities. Alamo strives to provide the highest standard in allograft tissue while continually honoring the gift of donation. For mor information visit https://alamobiologics.com/.
About Australian Biotechnologies: Australian Biotechnologies is the largest biological tissue processor in Australia, producing over 20,000 bone and tissue allograft products annually. Working with key Australian Donation Partners, our allografts offer life enhancing possibilities in orthopedic, sports medicine, spine, foot and ankle, reconstructive trauma, oral and dental procedures. Headquartered in Sydney Australia and supplies allografts to Australia and New Zealand. For more information visit www.ausbiotech.com.au.
About Cornell University: Cornell University is a world-class research institution known for the breadth and rigor of its curricula, and an academic culture dedicated to preparing students to be well-educated and well-rounded citizens of the world. Its faculty, staff and students believe in the critical importance of knowledge—both theoretical and applied—as a means of improving the human condition and solving the world’s problems. With campuses in Ithaca, New York and New York City, and a location in Doha, Qatar, Cornell is a private, Ivy League research university and the land-grant institution of New York State.
AboutNew York State Center for Advanced Technology: NYS CAT is a NYSTAR-supported program to encourage greater collaboration between private industry and universities in the development and application of new technologies. The CAT program, created in 1983, facilitates a continuing program of basic and applied research, development, and technology transfer in multiple technological areas, in collaboration with and through the support of private industry. CATs play a critical role in spurring technology-based applied research and economic development in the state; promoting national and international research collaboration and innovation; and leveraging New York’s research expertise and funding with investments from the federal government, foundations, businesses, venture capital firms and other entities. The Center for Life Science Enterprise at Cornell University, Cornell’s CAT, pursues programs addressing the economic development needs of New York’s biotech industry, partnering with companies in fields including bioengineering, diagnostics, medical devices, therapeutics, agriculture, and veterinary medicine since 1986.
Explore how innovative therapeutics are providing better treatment options.
JUPITER, Fla., Nov. 9, 2023 /PRNewswire-PRWeb/ — An upcoming episode of Advancements with Ted Danson will educate about improvements in diagnostic solutions and technologies for oncology and other difficult to treat diseases.
In this segment, viewers will learn what makes early detection a key driver to providing better treatment and higher survival rates. The show will explore how MMD Technologies, Inc. (MMD) uses Enhanced Molecular Delivery (EMD), with electrical fields, to mediate the delivery of therapeutics at the cellular level.
Viewers will see how MMD’s patented EMD technology (IntellipulseTM) moderately raises the temperature of the tissue being treated to a specific level, measuring impedance feedback in real time, while applying minimal electrical fields, therefore eliminating the potential for over or under treating. The segment will also explore how MMD’s patented changes cause higher efficacy without systemic side effects.
“The next generation platform (IntellipulseTM system) being developed by MMD will enhance reliability of the delivery process, resulting in increased efficacy, leading to better therapeutic outcomes,” remarked Richard Heller, Ph.D., Chief Science Officer, MMD Technologies.
In addition, spectators will learn how MMD’s platform uses gene therapy, vaccines, and plasmid DNA to deliver therapeutics for other diseases and disorders outside of cancer.
“We look forward to sharing how more than 40 years of research has resulted in a new approach that is helping to treat patients at the cellular level,” said John Galvin, senior producer for the Advancements series.
About MMD Technologies: Headquartered in Tampa, Florida, MMD was founded in a quest to bring meaningful change to an old technology. MMD has developed an efficient method for delivering therapeutic or prophylactic agents, either in the form of proteins or plasmid DNA (genes) for the purposes of vaccination and therapy for indications such as cancer, cardiovascular, wounds and infectious diseases. With more than 25 years of research, MMD has created a series of patents that make these important changes possible.
About Advancements and DMG Productions: Advancements is an information-based educational television series that explores recent developments taking place across several industries and economies. Shining a light on important issues and topics impacting society today, the series features the cutting-edge improvements, state-of-the-art technologies, and innovative solutions responsible for shaping, molding, and transforming our world.
Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming for viewers and networks.
Goldfarb was diagnosed with melanoma for a third time in January 2011 — 11 weeks after giving birth to her son, Kai. The cancer had reached stage 4 by metastasizing to her liver and pancreas, and Goldfarb enrolled in a clinical trial for tumor-infiltrating lymphocyte (TIL) therapy as part of her treatment.
Because of the clinical trial, she reached no evidence of disease two years post treatment (during which time the 40-plus tumors all over her body shrank until they disappeared) and has remained disease free for the past 11 years.
Throughout her experience, Goldfarb realized not all patients are aware of clinical research opportunities that may be available to them, especially in oncology. As a result, she embraced the opportunity to be a vocal patient advocate even outside of her professional responsibilities in clinical trial patient recruitment by speaking at industry and patient conferences, writing articles and white papers, speaking with the media about the importance of clinical trials, and working one-on-one with people with cancer to help them navigate their treatment options.
“This is a humbling recognition for something I’m very passionate about,” Goldfarb said. “I don’t share my story because I want to be in the spotlight. I do it because a clinical trial saved my life, yet less than 5% of patients with cancer ever participate in clinical research. I want everyone to understand the power and potential of clinical trials as a treatment option — and more importantly, I want to provide hope and clarity to anyone who feels like they’re up against the odds during a discouraging and confusing time.”
Goldfarb gave the keynote address at the Melanoma Research Alliance’s (MRA) annual scientific retreat in Washington, D.C., in March and has spoken about how medical professionals must improve awareness of clinical trials among patients at various industry events.
Goldfarb has been a research advocate for the National Cancer Institute (NCI), which uses her perspective to ensure the patient’s experience is considered throughout the research process. She is one of the patient moderators of the MRA’s patient forum, and created patient-centric online clinical trial resources for the organization as well as several top-20 global pharmaceutical companies. She is also heavily involved with the Melanoma International Foundation (MIF), the Melanoma Research Foundation (MRF), the Alliance for Regenerative Medicine (ARM), the Association of Clinical Research Professionals (ACRP), and Imerman Angels. She and her husband, Jeff, have met with members of Congress to push for increased funding for the NCI and National Institutes of Health (NIH).
As valuable as her public advocacy work is, Goldfarb believes one-on-one outreach with patients makes the greatest difference. She helps them navigate their treatment options, including how medical research works, what a clinical trial is, and whether it’s right for them. She then connects them with others battling cancer so they can build a stronger support system.
“In a sea of worthy and passionate candidates, there’s no one more deserving than Jamie,” said Matt Walz, CEO of Trialbee. “It’s not just about how she has carried herself in the face of tremendous adversity. It’s about how she has channeled her struggles into empowering and uplifting others facing similar battles. Jamie embodies hope and resiliency in the most inspiring way. She’s been an incredible asset to the Trialbee family, and we are lucky to have her.”
Goldfarb accepted the Linnea Olson Award at the Medidata NEXT New York conference at the Sheraton New York Times Square Hotel on November 7.
“I just want patients to always remember they are not alone,” Goldfarb said. “Talk to friends. Family. Healthcare providers. Don’t stop talking until you understand all your options.”
About Trialbee
Trialbee is revolutionizing the patient recruitment ecosystem with technology, people, and passion. The company’s vendor-agnostic Honey Platform™ is a SaaS Patient Recruitment Platform that centralizes and standardizes all recruitment activities from every source, channel, and partner from interest through enrollment – providing unprecedented transparency and actionable insights for real-time patient tracking, higher-quality referrals that reduce site burden, and robust ROI reporting. Honey is surrounded by a team of Precision Recruitment experts who meet patients where they are in their journey with data-driven modeling based on consumer behavior and other real-world data, hyper-targeted digital outreach, two-step pre-qualification, and meaningful Omnichannel partners focused on patient advocacy, community engagement, and diversity. To take control of patient recruitment for your next study, visit http://www.trialbee.com/.
In this free webinar, gain insights for maximizing the impact that solution providers and other channel partners can have on the patient experience.
/PRNewswire-PRWeb/ — Join this fireside chat with Mike McDole from Aveo, an oncology-focused biopharmaceutical company who will discuss challenges and opportunities when it comes to trade operations and growing the customer base. Be a part of this discussion on ways to optimize trade operations and patient management through a centralized patient aggregation solution and opportunities for maximizing the impact that solution providers and other channel partners can have on the patient experience.
Join Michael McDole, Executive Director, Head of Trade & Distribution, AVEO Oncology; and James Kahan, Director of Customer Success, Claritas Rx, for the live webinar on Monday, November 20, 2023, at 1pm EST (10am PST).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
“At Memorial Hermann, we are committed to continuously improving care for patients across our community,” says Feby Abraham, PhD, executive vice president and chief strategy officer for Memorial Hermann Health System. “AdaptX transforms clinical management by empowering clinical leaders to continuously assess, improve, and manage care with their own real-world data. We are excited not only to invest in AdaptX but also to use their solutions to enhance our care capacity and quality.”
“AdaptX has achieved tremendous growth across the health system market,” says YB Choi, partner at Cercano Management. “We are excited to deepen our support of AdaptX as it deploys its self-serve clinical management solutions across acute and ambulatory care environments in the U.S. and internationally.”
“Healthcare leaders are using AdaptX to deliver solutions for their greatest challenges: increasing capacity and access, improving quality, enhancing equity, reducing burnout, and reducing greenhouse emissions,” says Dan Low, MD, chief medical officer of AdaptX. “AdaptX has proven that our solutions catalyze dramatic improvements for any health system, from large-scale academic environments to much smaller rural communities.”
“We are thrilled with the fantastic support of our new and returning investors,” says Warren Ratliff, chief executive officer of AdaptX. “It is a testament to the incredible work of AdaptX’s team that our fundraising round was oversubscribed despite the challenging economic environment.”
About AdaptX
With AdaptX’s self-serve Adaptive Clinical Management™ solution, health systems transform clinical management, delivering dramatically better patient care and financial results. AdaptX’s AI-driven Mission Control Center™ empowers clinical leaders to quickly and easily leverage their real-world data to assess performance, compare approaches, and adapt – across patients, teams, protocols, workflows, and facilities.
AdaptX is headquartered in Seattle and was founded in 2016. Learn more at adaptx.com.
About Memorial Hermann
Charting a better future. A future that’s built upon the HEALTH of our community. This is the driving force for Memorial Hermann, redefining health care for the individuals and many diverse populations we serve. Our 6,600 affiliated physicians and more than 33,000 employees practice the highest standards of safe, evidence-based, quality care to provide a personalized and outcome-oriented experience across our more than 250 care delivery sites. As one of the largest not-for-profit health systems in Southeast Texas, Memorial Hermann has an award-winning and nationally acclaimed Accountable Care Organization, 17* hospitals and numerous specialty programs and services conveniently located throughout the Greater Houston area. Now and for generations to come, the health of our community will be at the center of what we do – charting a better future for all.
*Memorial Hermann Health System owns and operates 14 hospitals and has joint ventures with three other hospital facilities, including Memorial Hermann Surgical Hospital First Colony, Memorial Hermann Surgical Hospital Kingwood and Memorial Hermann Rehabilitation Hospital-Katy.
Media Contact
Courtney Witter, AdaptX, 1 206-620-0233, [email protected], adaptx.com
WASHINGTON and SAN FRANCISCO, Oct. 31, 2023 /PRNewswire/ — For the third consecutive year, Martis Capital Management, LLC (Martis Capital), a healthcare-focused private equity firm, has been named to Inc. magazine’s Founder-Friendly Investors list, recognizing the private equity and…
